The role of the TIGIT immune checkpoint axis in susceptibility to infection in decompensated cirrhosis

点击翻译按钮获取中文摘要

One in ten people in the UK have liver disease and the progressive development of liver damage can lead ultimately to cirrhosis. Patients with cirrhosis can remain well for many years but a proportion will develop complications such as ascites (fluid in the abdomen), upper gastrointestinal bleeding, encephalopathy (a state of confusion), or jaundice. This is called decompensated cirrhosis and if this causes other organs in the body to fail then it is termed acute-on-chronic liver failure. One of the most profound consequences of decompensated cirrhosis and acute-on-chronic liver failure is that patients are highly susceptible to infections. Infections in these patients have a very poor prognosis with a high mortality, even with antibiotic treatment. Therefore it is important to try to understand why these patients are more susceptible to infections in the first place so we can develop new treatments. An interesting observation in patients with decompensated cirrhosis is that although their immune system is highly activated, the immune cells do not fight infections well. Our theory is that this, in part, is because the cells have a higher level of a type of molecule called immune checkpoints. Immune checkpoints act as the "brake" on the immune system and while they can be helpful to prevent damage from an over-active immune system, too much can hamper the immune system's ability to fight diseases. Cancer cells have higher levels of immune checkpoints and a new type of cancer treatment ("immunotherapy") works by blocking immune checkpoints.We are interested in a particular group of immune checkpoints collectively called the "TIGIT axis" on T cells, a key type of immune cell that fights infections and coordinates immune responses. These immune checkpoints have been shown to impair T cell function against cancer and chronic viral infections (like HIV). To investigate our theory that they are also involved in poor T cell functions in decompensated liver disease, we will look at the levels of the TIGIT axis immune checkpoints on T cells that we find in blood, the liver, and in ascites (the fluid that collects in the abdomen). We will then go on to investigate if having more of these immune checkpoints makes the T cells less effective, and if we can improve this by blocking the immune checkpoints.We will recruit patients from outpatient clinics or who are admitted to hospital. With their consent we will collect samples of blood and ascites, and collect data about their medical history and medication. If they have a liver biopsy to diagnose their condition, then we will ask to use part of the sample. We will follow them up for up to 1 years after they join the study.Overall, the intended benefit is that if we can identify a particular immune checkpoint then it could be a target for new medication to reset the immune system in patients with decompensated cirrhosis and reduce their susceptibility to infection.